Patent 5087624 Issued on February 11, 1992. Estimated Expiration Date: July 13, 2010. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
The administration of chromic picolinate, preferably in the form of chromic tripicolinate, as a prophylactic or therapeutic agent for controlling various blood serum parameters. In particular, the administration is for controlling blood serum lipid levels, including the lowering of undesirably high blood serum LDL-cholesterol levels and the raising of blood serum HDL-cholesterol levels. Additionally, the administration is for controlling undesirable high blood serum glucose levels, this being particularly applicable for the treatment of maturity-onset diabetes. Additionally, chromic picolinate, preferably in the form of chromic tripicolinate, is administered to facilitate uptake of amino acids by skeletal muscle. Thus chromic picolinate can act as an effective anabolic agent.
Other References
Garrison et al., The Nutrition Desk Reference, (1985), pp. 18-21
Recommended Dietary Allowances, 9th Revised Ed., The National Academy of Sciences (1980), pp. 159-161
Albers, J. J. et al., (1978) Clin. Chem. 24:853-856
Friedewald, W. T., (1972) Clin. Chem. 18:499-502
Naito, H. K., (1986) J. Clin. Immunoassay 9:11-20
Clegg, M. D. and Schroeder, W. A., (1959) J. Amer. Chem. Soc. 81: 6065-6069
Hills, M. et al., (1979) Brit. Jour. Clin. Pharmacol. 8:7-20
Newman, W. P. et al., (1986) New England J. of Med. 314:138-144
Avogaro, P/ et al., (1978) Artery 4:385-394
Sniderman, A. et al., (1980) Proc. Natl. Acad. Sci. USA 77:604-608
Riesen, W. F. et al., (1980) Atherosclerosis 37:157-162
De Backer, G. et al., (1982) Atherosclerosis 42:197-203
Maciejko, J. J. et al., (1983) New Engl. J. Med. 309:385-389
Schmidt, S. B. et al., (1985) Am. J. Cardiol. 55:1459-1462
Kwiterovich, P. O. et al., (1983) Preventive Medicine 12:815-834
Brunzell, J. D. et al., (1984) Atherosclerosis 4:79-83
Anderson, R. A. et al., (1985) Amer. J. Clin. Nutr. 41:1177-1183
Schaller, K. H., (1973) At. Absorption Newsletter 12:147-150
Evans, G. W., (1980) Pediatric Res. 14:876-880
Offenbacher, E. G. and Pi-Sunyer, F. X., (1988) Ann. Rev. Nutr. 8:543-563
Mertz, W., Nutrition Reviews 33(5):129-135. See also Abstract Citations 2535 and 2537, (1975)
Seal, C. J. and Heaton, F. W., (1983) Brit. Journal of Nutrition 50:317-324
Chemical Abstracts citation 88:163086 (1977)
Toepfer, E. W. et al., J. Agr. Food Chem. 21(1):69-73 (1973)
Anderson, R. A. et al., Federation Proceedings 43:484 (1984)
Gurson, C. T. et al., Amer. J. of Clin. Nutri., 26:988-991 (1973)
Schroeder, H. A., J. Nutrition 88:439-445 (1966)
National Research Council Recommended Daily Allowances, 10th revised Edition, National Academy of Sciences, Washington, D.C. (1989)
Elwood, J. C. et al., J. Amer. Coll. of Nutri. 1:263-274 (1982)
Abraham, A. et al., The Amer. J. of Clin. Nutri. 33:2294-2298 (1980)
Simonoff, M. et al., Biolog. Trace Element Res. 6:431-439 (1984)
Evans, Gary W., International Journal of Biosocial and Medical Research 11(2):163-180 (1989)
Press, R. I. et al., Western Journal of Medicine 152:41-45 (1990)
Nutrition 21 consumer education brochure: "The Prophylactic and Therapeutic Potential of Chromium Picolinate in Diabetes, Hyperlipidemia, Anabolism and Weight Reduction," (1991)
Present Knowledge in Nutrition, 5th Ed. The Nutrition Foundation (1984), pp. 571-582
Boyle et al., (1977) Southern Med., Jour. 70:1449-1453
Anderson, R. A., Clin. Physiol. Biochem. 4:31-41 (1986)
Riales, R., in Chromium in Nutrition and Metabolism, (Shapcott and Hubert, Eds., (1979), pp. 199-212
Newman, H. A. I. et al., (1978) Clin. Chem. 24:541-544
The Lipid Research Clinics Coronary Primary Prevention Trial Results, (1984) J. A. M. A. (J. Amer. Med. Assn.) 251:351-364
McCarty, Mark F. Medical Hypothesis 6:1177-1189. (1980
July 13, 2010. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
